Despite recent therapeutic advances in cancer treatment, metastatic cancer remains the primary cause of cancer deaths.
Researchers at Purdue University have developed chimeric antigen receptor (CAR) neutrophils for the targeted treatment of cancer.
Researchers at Purdue University have developed selective small molecule inhibitors of G protein-coupled receptor kinase 5 (GRK5) for preventing heart failure and treating breast cancer.
Medical College of Wisconsin inventors have developed novel small molecule therapeutics that will help treat small cell lung cancer, among other cancers.
Medical College of Wisconsin inventors have developed a novel biotherapeutic for eliminating antibiotic-resistant enterococci from the GI tract.
Remdesivir is currently the only FDA-approved drug for treating COVID-19. While remdesivir improves recovery time, it does not significantly reduce death rates in hospitalized adults. Researchers at the University of Kansas have produced novel antivirals that shows promise as a COVID-19 treatment.
SVC112 is a late-preclinical stage asset with potent single agent activity in genetically-defined models of salivary gland cancer, a neglected and orphan disease with no approved targeted or immunotherapy agents.
Mayo Clinic researchers have developed a small molecule modulator for use in treating and preventing a variety of Wnt-related conditions such as Alzheimer’s Disease (AD) and other neurodegenerative disorders, traumatic and ischemic brain injury, as well as bone loss disorders.
Microparticles based on hydroxyapatite, calcium carbonate, or calcium citrate and cross-linked gels loaded with a drug such as eugenol or arginine are able to occlude dentinal tubules and release on-demand a cargo drug to the oral cavity and to the pulp of the tooth, providing both desensitizing, antibacterial or any other effect depending on the drug cargo.